{"id":"b553bad1-52b1-4096-b537-da7460d39812","name":"NeuroPace","slug":"neuropace","description":"NeuroPace (NASDAQ: NPCE) is a Mountain View-based medical device company that developed the [RNS System](/models/rns-system), the only FDA-approved brain-responsive neuromodulation device for treating drug-resistant focal epilepsy. Over 8,000 patients implanted. FY2025 revenue: 00M (25% YoY growth). 230+ Level 4 Comprehensive Epilepsy Centers in the US.","status":null,"founded":null,"hq":"Mountain View, California, USA","hqLat":null,"hqLng":null,"hqGeocodedAt":null,"hqAddress":null,"hqPrecision":null,"website":"neuropace.com","fundingTotal":null,"type":"hardware","reviewStatus":"reviewed","lifecycleState":"active","supersededByCompanyId":null,"sources":[{"url":"https://www.epilepsy.com/stories/fda-approves-responsive-neurostimulation-therapy-neuropace","title":"FDA Approves Responsive Neurostimulation Therapy by NeuroPace","sourceName":"Epilepsy Foundation"}],"keyFacts":[{"label":"FDA","value":"PMA approved (P100026)"},{"label":"Product","value":"RNS System"},{"label":"Indication","value":"Drug-resistant focal epilepsy (18+)"},{"label":"Type","value":"Closed-loop brain-computer interface"}],"aliases":[],"collisionRisk":"low","reviewNote":null,"atsProvider":null,"atsSlug":null,"factoryLocations":null,"manufacturingCapacity":null,"orgType":null,"burnSignal":null,"litigationEvents":null,"insurancePostureDisclosed":null,"unitEconomicsDisclosed":null,"tickerSymbol":null,"stockExchange":null,"secCik":null,"revenueUsd":null,"revenueBasis":null,"revenueAsOf":null,"employeeCount":null,"employeeCountBasis":null,"employeeCountAsOf":null,"marketCapUsd":null,"marketCapAsOf":null,"marketCapSource":null,"createdAt":"2026-08-08T22:30:24.195Z","updatedAt":"2026-08-08T22:41:09.646Z","jsonLd":{"@context":"https://schema.org","@type":"Organization","@id":"https://registry.deploy.report/companies/neuropace","url":"https://registry.deploy.report/companies/neuropace","name":"NeuroPace","description":"NeuroPace (NASDAQ: NPCE) is a Mountain View-based medical device company that developed the [RNS System](/models/rns-system), the only FDA-approved brain-responsive neuromodulation device for treating drug-resistant focal epilepsy. Over 8,000 patients implanted. FY2025 revenue: 00M (25% YoY growth). 230+ Level 4 Comprehensive Epilepsy Centers in the US.","identifier":"b553bad1-52b1-4096-b537-da7460d39812","address":"Mountain View, California, USA","publisher":{"@id":"https://deploy.report/#organization"}},"framework_metadata":{"framework_schema_version":"0.1.0","verification_status":"verified","maturity_stage":null,"lifecycle_state":null,"architectural_position":{"cohort":null,"sub_cohorts":[]},"within_cohort_verified_vs_claimed_pair":null,"cap_flags":[],"verification_depth":{"sources_count":1,"primary_source_types":[]}}}